Home » Topics » BioWorld Science, Neurology/psychiatric

BioWorld Science, Neurology/psychiatric
RSS

AM-101 begins phase I/II study for tinnitus

Feb. 27, 2007

Novel analgesic agents imparted in recent Merck patent

Feb. 27, 2007

Vyvanse approved for ADHD

Feb. 26, 2007

Valeant files IND for Cesamet in chemotherapy-induced neuropathic pain

Feb. 26, 2007

TorreyPines and Eisai extend Alzheimer's disease collaboration

Feb. 26, 2007

Indena patents novel compounds for treating skeletal muscle spasms

Feb. 23, 2007

Allon files IND for AL-108 phase II trials in schizophrenia

Feb. 22, 2007

SD-118 for neuropathic pain completes preclinical testing

Feb. 22, 2007

Hana anticipates delay in launch of Zensana

Feb. 22, 2007

Association between dopamine agonist use and pathological gambling in RLS

Feb. 22, 2007

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 30, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 30, 2025.
Researchers discover how glioblastoma tumors dodge chemotherapy
BioWorld MedTech
Researchers at the University of Sydney have uncovered a mechanism that may explain why glioblastoma returns after treatment, and the world-first discovery offers...
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...